God, AIDS, Africa & HOPE

Reflections / Gedanken

Desmond Tutu pleads with Obama…

Desmond Tutu 2007 at the Deutscher Evangelisch...

Desmond Tutu 2007 at the Deutscher Evangelischer Kirchentag in Cologne 2007 (Photo credit: Wikipedia)

The Nobel Peace Prize winner urges the U.S. president to increase global access to antiretrovirals:
“We are making historic progress against HIV/AIDS: The global rate of new HIV infections has levelled, and the number of annual AIDS deaths has decreased by nearly a third since 2005. Antiretroviral drugs are driving these gains by stopping progression of the disease and, we now know, preventing the spread of HIV infections. Yet AIDS remains the leading cause of death in sub-Saharan Africa, where poverty limits access to lifesaving treatments and 25 million people are living with HIV—representing 70 percent of cases worldwide. President Barack Obama should be commended for uniting the world behind the goal of creating an AIDS-free generation. I share his passion and believe we can achieve this in the next decade—but only if we accelerate the provision of antiretrovirals to the poorest and most vulnerable people. The opportunity has never been clearer. New data published in the New England Journal of Medicine project that early treatment with antiretrovirals in South Africa, my home country, would prove very cost-effective over a lifetime (costing $590 per life-year saved) and generate both public health and economic benefits. The World Health Organization (WHO) now recommends early and preventive treatment with antiretrovirals, including administration to children and uninfected partners of people living with the disease. The WHO estimates that this could save an additional 3 million lives and prevent at least as many new HIV infections through 2025…”

Read the complete plea of Desmond Tutu on politico.com: http://www.politico.com/magazine/story/2013/11/keys-to-defeating-hivaids-100006.html
or POZ.com
http://www.poz.com/articles/desmond_tutu_2676_24819.shtml

Filed under: HIV and AIDS, HIV Prevention, HIV Treatment, Politics and Society, , , , , , , , , , , , ,

ARV pill prevents HIV – so a study tells…

In Uganda, a trial concluded that taking anti-retroviral treatment as a prevention measure on a daily base means to get almost total protection of HIV. This was reported by the online journal Plos these days.750 Ugandans, being themselves negative but with a positive life partner, were observed for one year while taking Truvada as a prevention tool and nobody of them was infected after one year. In the control group of 404 individuals, 14 persons became infected in the same time-frame.
“This is very exciting and compelling and confirms other studies in which people who took their tablets got almost total protection”, so Wits Reproductive Health and Research Institute Prof Francoise Venter. The question remains whether it is enough to treat only the infected partner or both to achieve such a result on the long run.

Filed under: HIV and AIDS, HIV Prevention, HIV Treatment, Medical and Research, , , , , , , , , , , , , , , , ,

HIV vaccine completes phase I trial

The time-course of an immune response begins w...

The time-course of an immune response begins with the initial pathogen encounter, (or initial vaccination) and leads to the formation and maintenance of active immunological memory. (Photo credit: Wikipedia)

Sometimes there are good news one comes across while doing the early morning snatch on news on the internet  – news which just give this ray of hope. This one is certainly giving this ray of hope, even if success is still in the dark and not guaranteed. It’s about a vaccine, called SAV001-H, the result of a collaboration between Western University in London, Ontario, and Sumagen Canada Inc. In a randomized, observer-blinded, placebo-controlled study, the team examined the vaccine’s safety, tolerability and immune responses in HIV-positive adults between the ages of 18 and 50. And guess what: no significant adverse side effects discovered during trial period and researchers found that, following vaccination, the antibody against HIV’s p24 capsid antigen increased by a factor as great as 64 and the antibody against the virus’s gp120 surface antigen rose up to eightfold. These levels remained raised throughout the year-long study period.

This is good news on several layers: First of all there are people out there working on a vaccine and don’t give up. Second there will be now trial phase II. And there is an invitation attached: “We are opening the gate to pharmaceutical companies, government and charity organization for collaboration to be one step closer to the first commercialized HIV vaccine”, so Jung-Gee Cho, CEO of Sumagen.

Well, let’s support such efforts by all means possible.  And if one is interested to read more on the subject click here.

Filed under: HIV Prevention, HIV Treatment, Medical and Research, , , , , , , ,

HIV & TB: Supply problems in South Africa

English: Coat of Arms of South Africa Deutsch:...

English: Coat of Arms of South Africa – Wikipedia)

HIV activist groups in South Africa are calling on the Minister of Health to address drug supply chain problems which are causing HIV and tuberculosis (TB) drug stock-outs in the country’s Eastern Cape province. According to a report launched at the 6th South African AIDS Conference by a coalition consisting of the Rural Health Advocacy Project (RHAP), Doctors Without Borders (MSF), the Treatment Action Campaign (TAC) and SECTION 27, 40% of the 70 facilities surveyed by MSF and TAC during May 2013 in the Mthatha catchment area in the Eastern Cape province had experienced HIV and/or TB drug stock-outs. More than 100,000 people, on antiretrovirals (ARVs) or TB treatment, depend on 300 facilities served by the Mthatha depot. Medical staff at 24% of the affected facilities were forced to send patients home without treatment because they experienced stock-outs of essential HIV and TB drugs. These stock-outs were reported to last, on average, 45 days at a time and have been ongoing since October 2012. The organisations estimated that at least 5494 adults were not able to take some of their ARVs and 561 children were sent home without treatment since September 2012 when the drug supply issues began. Lamivudine (3TC), tenofovir, nevirapine, efavirenz, paediatric ARV formulations and Rifafour (a fixed-dose combination of four TB drugs) are the main medications affected. “This situation is catastrophic. It means many thousands of people living with HIV have risked treatment interruption for months now. The stock-outs consequently undermine clinical benefits of life-saving ARV treatment. Over time, more deaths will occur as a result and the likelihood of increased drug resistance is significant,” says Dr Amir Shroufi, Deputy Medical Co-ordinator for MSF in South Africa. There have been a number of reports of patients receiving dual or even monotherapy in the Eastern Cape and Gauteng. “I have been taking ARVs since 2008. Each year this [a stock-out] happens at least six times. I go to the clinic and they tell me there is no medication for me,” said a 36 year-old unemployed man who lives in a rural village in the Eastern Cape. “It is very difficult for patients. We are telling them to adhere, but when they arrive at the clinic, which can take up to two hours to access by car in the rural Eastern Cape areas, they are told there is nothing for them and that they must come back another time,” said Vuyokazi Gonyela, the TAC Eastern Cape District Organiser. On 10 October 2012, staff at Mthatha depot in the Eastern Cape staged a strike, following which 29 individuals were suspended, leaving the depot with only 10 working employees. Coupled with chronic supply chain issues, this precipitated widespread drug stock-outs in the region. The survey followed an intervention by MSF and TAC volunteers during December 2012, which continued for three months, to respond to the burgeoning Mthatha depot crisis by supporting staffing, managing and ensuring drug delivery at the depot. This intervention helped to clear the backlog of drug orders and to bring the depot closer to normal levels of functioning. “The MSF/TAC emergency intervention in the Mthatha depot from December 2012 to March 2013 has shown that it is possible to correct a disastrous situation with limited resources, even if the impact remains short-lived without large systemic  changes and action from the provincial Department of Health”, said Gonyela, who led the intervention. The main causes for the drug supply problems are the lack of an early warning system for facilities to be able to report potential shortages, drug suppliers failing to meet tender quotas, government failing to pay suppliers, and poor ordering practices at health facilities and medicine depots. South Africa has one of the largest ARV programmes in the world with over 2 million people initiated on ARVs in the public sector. However, drug stock-outs are occurring across the country and are not limited to HIV and TB medication, but extend to other basic chronic medication such as hypertension (blood pressure) and diabetes medication, according to Dr Francois Venter, Deputy Director of the Wits Reproductive Health and HIV Institute (WHRI). This was reiterated by a number of healthcare workers attending the conference. “The national Department of Health should create an emergency team to respond to stock-outs – given the extent, importance, and frequency of essential drugs stock-outs nationwide,” said John Stephens of SECTION 27. The organisations are recommending that when stock-outs are identified, the underlying reasons must be established for each and appropriate action undertaken, and the individuals responsible for the stock-outs must be clearly identified. In response to the drug supply problems, the organisations have set up a civil society monitoring group which will focus on solving the drug supply problems and continue monitoring drug supply across the country. “We are aware of the drug stock-outs across the country and share your concerns,” said Helecine Snyman, Head of Affordable Medicines at the South African Department of Health.

© Copyright NAM — All rights reserved. Please photocopy and pass on.

Filed under: HIV and AIDS, HIV Prevention, HIV Treatment, Politics and Society, , , , , , , , , , , , , , , ,

And another thought of being undetectable & on treatment

Chronic Disease

Chronic Disease (Photo:tamahaji)

Dave R. from TheBody.com is reflecting on the question of undetectable and what it would mean for those being infected. There are recommendations but there is no certainty. There might be certainty after further studies and in the moment it looks good for those who say that being undetectable, on treatment and no STI’s are not infectious anymore. Have you ever thought what this would mean for those being HIV positive? It would mean that HIV treated proper would be equal like having cancer, being a diabetic and having any other chronic disease.  If, after indisputable proof, it would be widely reported that people on successful treatment are not in danger of passing on the virus, then there is no reason for every sexually active person on the planet not to get tested and if necessary treated because treatment will make you a safe person to have sex with. It would be a great argument for getting tested and on treatment. And it would diminish the stigma attached still to this condition. Undetectable = not infectious: this would change perception and consequences of HIV and AIDS. To read the interesting reflection of Dave R. click here.

Filed under: HIV and AIDS, HIV Prevention, HIV Treatment, Medical and Research, Politics and Society, Reflection, Religion and Ethics, Society and living environment, , , , , , , , ,

Blog Categories

Follow God, AIDS, Africa & HOPE on WordPress.com

You can share this blog in many ways..

Bookmark and Share

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,711 other subscribers

Translation – Deutsch? Française? Espanol? …

The translation button is located on each single blog page, Copy the text, click the button and paste it for instant translation:
Website Translation Widget

or for the translation of the front page:

* Click for Translation

Copyright

© Rev Fr Stefan Hippler and HIV, AIDS and HOPE.
Unauthorized use and/or duplication of this material without express and written permission from this blog’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Rev Fr Stefan Hippler and HIV, AIDS and HOPE with appropriate and specific direction to the original content.

This not withstanding the following applies:
Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 3.0 Unported License.